SI2987793T1 - Heterociklične amidne spojine ocetne kisline - Google Patents
Heterociklične amidne spojine ocetne kisline Download PDFInfo
- Publication number
- SI2987793T1 SI2987793T1 SI201430479T SI201430479T SI2987793T1 SI 2987793 T1 SI2987793 T1 SI 2987793T1 SI 201430479 T SI201430479 T SI 201430479T SI 201430479 T SI201430479 T SI 201430479T SI 2987793 T1 SI2987793 T1 SI 2987793T1
- Authority
- SI
- Slovenia
- Prior art keywords
- disease
- compound
- alkyl
- salt
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Claims (16)
- HETEROCIKLIČNE AMIDNE SPOJINE OCETNE KISLINE EP 2 987 793 B1 PATENTNI ZAHTEVKI1. Spojina s formulo (I) ali njena sol:(I) (kjer obroč A je benzenski obroč, R1 je Ci-6 alkil, halogen, halogeno-C-i-6 alkil, ali -O-halogeno-Ci-6 alkil, R2 je H ali halogen, R11, R12, R13 in R14 so enaki ali različni med seboj in so H, C1-6 alkil, halogen, halogeno-Ci-6 alkil, cikloalkil, -O-C1-6 alkil, ali -O-halogeno-Ci-6 alkil, Uje NR15 ali O, V je CH ali N, v primeru kjer U je O, V je N, R15 je H, C1-6 alkil, ali -C1-6 alkilen-OH, in X je O).
- 2. Spojina ali njena sol po zahtevku 1, kjer U je NR15, in V je N.
- 3. Spojina ali njena sol po zahtevku 2, kjer R1 je halogen, halogeno-Ci-e alkil, ali -O-halogeno-Ci-e alkil, in R11, R12, R13, in R14 so enaki ali različni med seboj in so H, halogen, halogeno- C1-6 alkil, cikloalkil, ali -O-halogeno-Ci-6 alkil.
- 4. Spojina ali njena sol po zahtevku 3, kjer R15 je H.
- 5. Spojina ali njena sol po zahtevku 4, kjer R1 je halogen ali halogeno-C-i-e alkil.
- 6. Spojina ali njena sol po zahtevku 5, kjer so R11, R12, R13 in R14 enaki ali različni med seboj in so H, halogen, ali halogeno-Ci-6 alkil.
- 7. Spojina ali njena sol po zahtevku 6, kjer R12 je halogen ali halogeno-Ci-e alkil, in R11, R13 in R14 so H.
- 8. Spojina ali njena sol po zahtevku 7, ki je izbrana iz naslednje skupine, ki jo sestavljajo: 2-(5-kloro-2-okso-1,3-benzoksazol-3(2H)-il)-N-metil-N-{[5-(trifluorometil)-1 H-benzimidazol-2-il]metil acetamid, N-[(5-kloro-1H-benzimidazol-2-il)metil]-2-(5-kloro-2-okso-1,3-benzoksazol- 3(2H)-il)-N-metilacetamid, 2-(5-kloro-4-fluoro-2-okso-1,3-benzoksazol-3(2H)-il)-N-metil-N-{[5-(trifluorometil)-1H-benzimidazol-2-il]metil}acetamid, N-[(5-bromo-1H-benzimidazol-2-il)metil]-2-(5-kloro-2-okso-1,3-benzoksazol-3(2H)-il)-N-metilacetamid, in N-[(5-kloro-1H-benzimidazol-2-il)metil]-N-metil-2-[2-okso-5- (trifluorometil)-1,3-benzoksazol-3(2H)-il]acetamid.
- 9. Spojina ali njena sol po zahtevku 8, ki je 2-(5-kloro-2-okso-1,3-benzoksazol-3(2H)-il)-N-metil-N-{[5-(trifluorometil)-1H-benzimidazol-2-il]metil} acetamid hidroklorid.
- 10. Spojina ali njena sol po zahtevku 8, ki je 2-(5-kloro-4-fluoro-2-okso-1,3-benzoksazol-3(2H)-il)-N-metil-N-{[5-(trifluorometil)-1H-benzimidazol-2-il]metil} acetamid.
- 11. Spojina ali njena sol po zahtevku 8, ki je N-[(5-bromo-1 H-benzimidazol-2-il)metil]-2-(5-kloro-2-okso-1,3-benzoksazol-3(2H)-il)-N-metilacetamid.
- 12. Farmacevtski sestavek, ki obsega spojino ali njeno sol po zahtevku 1 in farmacevtsko sprejemljivo pomožno snov.
- 13. Farmacevtski sestavek po zahtevku 12, ki je alosterski modulator z pozitivnim dopaminskim receptorjem D1.
- 14. Farmacevtski sestavek po zahtevku 12 za uporabo pri preprečevanju ali zdravljenju bolezni, izbrane iz skupine, ki jo sestavljajo kognitivna okvara, negativni simptomi shizofrenije, Parkinsonova bolezen, Alzheimerjeva bolezen, Huntingtonova bolezen in odvisnosti od drog.
- 15. Uporaba spojine ali njene soli po zahtevku 1 za pripravo farmacevtskega sestavka za preprečevanje ali zdravljenje bolezni, izbrane iz skupine, ki jo sestavljajo kognitivna okvara, negativni simptomi shizofrenije, Parkinsonova bolezen, Alzheimerjeva bolezen, Huntingtonova bolezen in odvisnosti od drog.
- 16. Spojina ali njena sol po zahtevku 1 za uporabo pri postopku za preprečevanje ali zdravljenje bolezni, izbrane iz skupine, ki jo sestavljajo kognitivna okvara, negativni simptomi shizofrenije, Parkinsonova bolezen, Alzheimerjeva bolezen, Huntingtonova bolezen in odvisnosti od drog.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013087151 | 2013-04-18 | ||
| PCT/JP2014/061007 WO2014171528A1 (ja) | 2013-04-18 | 2014-04-18 | ヘテロ環酢酸アミド化合物 |
| EP14786115.7A EP2987793B1 (en) | 2013-04-18 | 2014-04-18 | Heterocyclic acetic acid amide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2987793T1 true SI2987793T1 (sl) | 2018-02-28 |
Family
ID=51729480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430479T SI2987793T1 (sl) | 2013-04-18 | 2014-04-18 | Heterociklične amidne spojine ocetne kisline |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8937087B2 (sl) |
| EP (1) | EP2987793B1 (sl) |
| JP (1) | JP6252582B2 (sl) |
| KR (1) | KR102193247B1 (sl) |
| CN (1) | CN105121435B (sl) |
| AR (1) | AR095883A1 (sl) |
| AU (1) | AU2014254768B2 (sl) |
| BR (1) | BR112015026512B1 (sl) |
| CA (1) | CA2909783C (sl) |
| CY (1) | CY1119754T1 (sl) |
| DK (1) | DK2987793T3 (sl) |
| EA (1) | EA028968B1 (sl) |
| ES (1) | ES2651866T3 (sl) |
| HK (1) | HK1214248A1 (sl) |
| HR (1) | HRP20171786T1 (sl) |
| HU (1) | HUE036054T2 (sl) |
| IL (1) | IL241962B (sl) |
| LT (1) | LT2987793T (sl) |
| ME (1) | ME02891B (sl) |
| MX (1) | MX2015014646A (sl) |
| MY (1) | MY175971A (sl) |
| NO (1) | NO2987793T3 (sl) |
| NZ (1) | NZ713118A (sl) |
| PH (1) | PH12015502341B1 (sl) |
| PL (1) | PL2987793T3 (sl) |
| PT (1) | PT2987793T (sl) |
| RS (1) | RS56865B1 (sl) |
| SA (1) | SA515370015B1 (sl) |
| SG (1) | SG11201508448RA (sl) |
| SI (1) | SI2987793T1 (sl) |
| TW (1) | TWI625329B (sl) |
| UA (1) | UA116243C2 (sl) |
| WO (1) | WO2014171528A1 (sl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR105025A1 (es) * | 2015-06-19 | 2017-08-30 | Astellas Pharma Inc | Compuesto de imidazodiazepina |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| AU2019339186A1 (en) | 2018-09-13 | 2021-03-25 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| CN110590576A (zh) * | 2019-08-15 | 2019-12-20 | 安徽金禾实业股份有限公司 | 一种4-多氟代甲氧基邻苯二胺的制备方法 |
| CN114380709B (zh) * | 2021-12-31 | 2023-07-21 | 西北农林科技大学 | 4-氯-2-酰氨基酚的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2674524B1 (fr) * | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| EP1165557B1 (en) * | 1999-04-02 | 2004-09-29 | Neurogen Corporation | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS |
| US6627624B1 (en) | 1999-04-02 | 2003-09-30 | Neurogen Corporation | Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6380210B1 (en) | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| AUPQ309399A0 (en) | 1999-09-28 | 1999-10-21 | Fujisawa Pharmaceutical Co., Ltd. | Benzothiazoline derivatives |
| DE60234616D1 (de) | 2001-09-14 | 2010-01-14 | High Point Pharmaceuticals Llc | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren |
| US7361671B2 (en) | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
| JP3813152B2 (ja) * | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| DE602004013563D1 (de) | 2003-03-14 | 2008-06-19 | Merck & Co Inc | Rantagonisten |
| EP1719761A4 (en) * | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | NEW HETEROCYCLIC CONNECTION |
| EP1756071B1 (en) * | 2004-05-27 | 2009-08-26 | UCB Pharma S.A. | Benzoxazolone derivatives, processes for preparing them and their uses |
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US7576106B2 (en) | 2005-10-11 | 2009-08-18 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| CL2007002097A1 (es) | 2006-07-20 | 2008-01-18 | Smithkline Beecham Corp | Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras. |
| US7786157B2 (en) | 2007-03-16 | 2010-08-31 | Chemocentryx, Inc. | OXO-imidazolidines as modulators of chemokine receptors |
| DE102007026341A1 (de) * | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
-
2014
- 2014-04-16 AR ARP140101624A patent/AR095883A1/es active IP Right Grant
- 2014-04-17 TW TW103114022A patent/TWI625329B/zh active
- 2014-04-18 ME MEP-2017-277A patent/ME02891B/me unknown
- 2014-04-18 US US14/256,135 patent/US8937087B2/en active Active
- 2014-04-18 NZ NZ713118A patent/NZ713118A/en unknown
- 2014-04-18 SG SG11201508448RA patent/SG11201508448RA/en unknown
- 2014-04-18 JP JP2015512531A patent/JP6252582B2/ja active Active
- 2014-04-18 WO PCT/JP2014/061007 patent/WO2014171528A1/ja active Application Filing
- 2014-04-18 MY MYPI2015703694A patent/MY175971A/en unknown
- 2014-04-18 PT PT147861157T patent/PT2987793T/pt unknown
- 2014-04-18 DK DK14786115.7T patent/DK2987793T3/en active
- 2014-04-18 HU HUE14786115A patent/HUE036054T2/hu unknown
- 2014-04-18 EP EP14786115.7A patent/EP2987793B1/en active Active
- 2014-04-18 EA EA201591988A patent/EA028968B1/ru not_active IP Right Cessation
- 2014-04-18 NO NO14786115A patent/NO2987793T3/no unknown
- 2014-04-18 KR KR1020157027691A patent/KR102193247B1/ko active IP Right Grant
- 2014-04-18 AU AU2014254768A patent/AU2014254768B2/en not_active Ceased
- 2014-04-18 ES ES14786115.7T patent/ES2651866T3/es active Active
- 2014-04-18 SI SI201430479T patent/SI2987793T1/sl unknown
- 2014-04-18 RS RS20171324A patent/RS56865B1/sr unknown
- 2014-04-18 CA CA2909783A patent/CA2909783C/en active Active
- 2014-04-18 CN CN201480020846.XA patent/CN105121435B/zh active Active
- 2014-04-18 UA UAA201511337A patent/UA116243C2/uk unknown
- 2014-04-18 MX MX2015014646A patent/MX2015014646A/es active IP Right Grant
- 2014-04-18 BR BR112015026512-0A patent/BR112015026512B1/pt active IP Right Grant
- 2014-04-18 PL PL14786115T patent/PL2987793T3/pl unknown
- 2014-04-18 LT LTEP14786115.7T patent/LT2987793T/lt unknown
- 2014-10-28 US US14/525,982 patent/US9708307B2/en active Active
-
2015
- 2015-10-07 IL IL241962A patent/IL241962B/en active IP Right Grant
- 2015-10-08 PH PH12015502341A patent/PH12015502341B1/en unknown
- 2015-10-18 SA SA515370015A patent/SA515370015B1/ar unknown
-
2016
- 2016-02-23 HK HK16102028.4A patent/HK1214248A1/zh unknown
-
2017
- 2017-11-17 HR HRP20171786TT patent/HRP20171786T1/hr unknown
- 2017-12-06 CY CY20171101288T patent/CY1119754T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2987793T1 (sl) | Heterociklične amidne spojine ocetne kisline | |
| HRP20210459T1 (hr) | Supstituirani derivati oksopiridina | |
| RU2454411C2 (ru) | Производные хинолина | |
| HRP20180341T1 (hr) | Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd | |
| MX2009003410A (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih. | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| SI2989100T1 (sl) | Naftiridinski derivati, uporabni kot antagonisti integrina alfa-v-beta-6 | |
| HRP20220003T1 (hr) | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| NZ603364A (en) | Inhibitors of arginase and their therapeutic applications | |
| UY32695A (es) | FORMA DE DOSIFICACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN ORAL DE UN INHIBIDOR DE LA FAMILIA Bcl-2 | |
| HRP20140214T1 (hr) | Derivati tetrahidrokinolina za lijeäśenje posttraumatskog stresnog poremeä†aja | |
| NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| NZ612000A (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
| HRP20120867T1 (hr) | Selurampanel | |
| HRP20120046T1 (hr) | Nerameksan za uporabu kod liječenja subakutnog tinitusa | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| SI3009426T1 (sl) | Derivate 4-alkinilimidazola in zdravilo, ki ga vsebuje kot aktivno učinkovino | |
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич | |
| HRP20190624T1 (hr) | Pozitivni alosterni modulatori muskarinskog m1 receptora | |
| BR112013031121A2 (pt) | composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento | |
| JP2014517848A5 (sl) | ||
| JP2013542226A5 (sl) | ||
| SI2303264T1 (sl) | Metode zdravljenja alfa adrenergičnih posredovanih stanj z uporabo imidazolin derivatov |